Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future Treatment Options in PBC.

John M Vierling1

  • 1Baylor Liver Health, Baylor College of Medicine, Houston, TX 77030, USA. vierling@bcm.tmc.edu

Seminars in Liver Disease
|September 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Multiscale zonation-resolved modeling of dose-dependent determinants of acetaminophen-induced liver injury.

Frontiers in pharmacology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Clinical signs and symptoms of Wilson disease in a real-world cohort of patients in the United States: a medical chart review study.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Treatment patterns in a real-world cohort of patients with Wilson disease in the United States.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Current primary biliary cholangitis (PBC) treatments focus on slowing disease progression. Future therapies may involve antiretroviral, immunosuppressive, and immunomodulatory agents targeting autoimmune responses and inflammation.

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • The exact causes of primary biliary cholangitis (PBC) are not fully understood, and no cure currently exists.
  • Current management strategies for PBC primarily aim to prevent disease advancement, with ursodeoxycholic acid being a key therapeutic agent.
  • Emerging research suggests potential roles for retroviral infections and autoimmune T and B cell responses in PBC pathogenesis.

Purpose of the Study:

  • To explore novel therapeutic strategies for primary biliary cholangitis (PBC) beyond current disease-modifying treatments.
  • To investigate the potential of antiretroviral, immunosuppressive, and immunomodulatory agents in managing PBC.
  • To identify specific cellular and molecular pathways amenable to therapeutic intervention in PBC.

Main Methods:

Related Experiment Videos

  • Review of current understanding of PBC etiopathogenesis, including autoimmune and potential infectious components.
  • Analysis of promising therapeutic targets, such as T-cell activation, effector cell migration, cytokine and immunoglobulin pathways, and inflammation/oxidation.
  • Consideration of advanced immunomodulatory approaches, including T and B cell depletion and induction of immune tolerance.

Main Results:

  • Advances in understanding PBC pathogenesis provide a rationale for exploring new drug classes.
  • Specific targets for intervention include T-cell activation, effector cell trafficking, and inflammatory/oxidative processes.
  • Strategies like T and B cell modulation and immune tolerance induction show promise for managing PBC.

Conclusions:

  • New therapeutic avenues for PBC are emerging, focusing on modulating immune responses and inflammation.
  • Targeting specific immune pathways and employing immunomodulatory strategies may offer improved outcomes for PBC patients.
  • Preventing biliary fibrosis and inducing immune tolerance are key future goals in PBC management.